Encouraging Updated Findings of Pembrolizumab in Gastric and GEJ Cancer Presented Prior to FDA Decision
Yale Cancer Center/Smilow Cancer HospitalIn updated findings from the KEYNOTE-059 trial of pembrolizumab in advanced gastric or gastroesophageal junction (GEJ) cancer, the PD-1 inhibitor maintained signs of its clinical benefit in this patient population.